Tom 7, Nr 1 (2022)
Praca badawcza (oryginalna)
Opublikowany online: 2021-11-05

dostęp otwarty

Wyświetlenia strony 4989
Wyświetlenia/pobrania artykułu 132
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Prognostic significance of sex in patients with primary tracheal tumors – a retrospective, single-center study

Aleksandra Piórek1, Adam Płużański1, Dariusz Mirosław Kowalski1, Maciej Krzakowski1
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(1):12-16.

Streszczenie

Introduction.We aimed to assess the prognostic significance of the sex of patients with primary tracheal tumors based on our own results as well as the literature review.

Material and methods.We carried out a retrospective analysis of 89 patients with primary tracheal tumors treated at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, between January 2000 and December 2016. Men and women were compared in terms of overall survival, disease-free survival, and progression-free survival.

Results.In the entire study group, the median overall survival was 61.30 months in women and 8.55 months in men (p < 0.0001). 5-year overall survival rates were 2.1% in men versus 50.6% in women (p < 0.0001). Among those receiving radical treatment, women had improved survival rates compared with men. Sex was an independent prognostic factor in both the total study population and among those undergoing radical treatment.

Conclusions.According to our results, women with primary tracheal tumors have significantly better survival than men. Because female sex is an independent prognostic factor in patients with primary tracheal tumors, the ratio of women to men should be taken into consideration in reports comparing the outcomes of different treatments.

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. Junker K. Pathology of tracheal tumors. Thorac Surg Clin. 2014; 24(1): 7–11.
  2. Macchiarini P. Primary tracheal tumours. Lancet Oncol. 2006; 7(1): 83–91.
  3. Madariaga ML, Gaissert HA. Overview of malignant tracheal tumors. Ann Cardiothorac Surg. 2018; 7(2): 244–254.
  4. Webb BD, Walsh GL, Roberts DB, et al. Primary tracheal malignant neoplasms: the University of Texas MD Anderson Cancer Center experience. J Am Coll Surg. 2006; 202(2): 237–246.
  5. Mallick S, Benson R, Giridhar P, et al. Demography, patterns of care and survival outcomes in patients with malignant tumors of trachea: A systematic review and individual patient data analysis of 733 patients. Lung Cancer. 2019; 132: 87–93.
  6. Albers E, Lawrie T, Harrell JH, et al. Tracheobronchial adenoid cystic carcinoma: a clinicopathologic study of 14 cases. Chest. 2004; 125(3): 1160–1165.
  7. Honings J, Gaissert HA, Weinberg AC, et al. Prognostic value of pathologic characteristics and resection margins in tracheal adenoid cystic carcinoma. Eur J Cardiothorac Surg. 2010; 37(6): 1438–1444.
  8. Gaissert HA, Grillo HC, Shadmehr MB, et al. Long-term survival after resection of primary adenoid cystic and squamous cell carcinoma of the trachea and carina. Ann Thorac Surg. 2004; 78(6): 1889–96; discussion 1896.
  9. Regnard JF, Fourquier P, Levasseur P. Results and prognostic factors in resections of primary tracheal tumors: a multicenter retrospective study. The French Society of Cardiovascular Surgery. J Thorac Cardiovasc Surg. 1996; 111(4): 808–13; discussion 813.
  10. Wen J, Liu Di, Xu X, et al. Nomograms for predicting survival outcomes in patients with primary tracheal tumors: a large population-based analysis. Cancer Manag Res. 2018; 10: 6843–6856.
  11. Bhattacharyya N. Contemporary staging and prognosis for primary tracheal malignancies: a population-based analysis. Otolaryngol Head Neck Surg. 2004; 131(5): 639–642.
  12. Zhengjaiang L, Pingzhang T, Dechao Z, et al. Primary tracheal tumours: 21 years of experience at Peking Union Medical College, Beijing, China. J Laryngol Otol. 2008; 122(11): 1235–1240.
  13. Urdaneta AI, Yu JB, Wilson LD. Population based cancer registry analysis of primary tracheal carcinoma. Am J Clin Oncol. 2011; 34(1): 32–37.
  14. Napieralska A, Miszczyk L, Blamek S. Tracheal cancer - treatment results, prognostic factors and incidence of other neoplasms. Radiol Oncol. 2016; 50(4): 409–417.
  15. Makarewicz R, Mross M. Radiation therapy alone in the treatment of tumours of the trachea. Lung Cancer. 1998; 20(3): 169–174.
  16. Hetnał M, Kielaszek-Ćmiel A, Wolanin M, et al. Tracheal cancer: Role of radiation therapy. Rep Pract Oncol Radiother. 2010; 15(5): 113–118.
  17. Honings J, van Dijck JA, Verhagen AdF, et al. Incidence and treatment of tracheal cancer: a nationwide study in the Netherlands. Ann Surg Oncol. 2007; 14(2): 968–976.
  18. Manninen MP, Pukander JS, Flander MK, et al. Treatment of primary tracheal carcinoma in Finland in 1967-1985. Acta Oncol. 1993; 32(3): 277–282.
  19. Licht PB, Friis S, Pettersson G. Tracheal cancer in Denmark: a nationwide study. Eur J Cardiothorac Surg. 2001; 19(3): 339–345.
  20. Yang KY, Chen YM, Huang MH, et al. Revisit of primary malignant neoplasms of the trachea: clinical characteristics and survival analysis. Jpn J Clin Oncol. 1997; 27(5): 305–309.
  21. Chao MW, Smith JG, Laidlaw C, et al. Results of treating primary tumors of the trachea with radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 41(4): 779–785.
  22. Jeremic B, Shibamoto Y, Acimovic L, et al. Radiotherapy for primary squamous cell carcinoma of the trachea. Radiother Oncol. 1996; 41(2): 135–138.
  23. Mornex F, Coquard R, Danhier S, et al. Role of radiation therapy in the treatment of primary tracheal carcinoma. Int J Radiat Oncol Biol Phys. 1998; 41(2): 299–305.
  24. Agulnik M, Cohen EWE, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007; 25(25): 3978–3984.
  25. Lee JH, Jung EJ, Jeon K, et al. Treatment outcomes of patients with adenoid cystic carcinoma of the airway. Lung Cancer. 2011; 72(2): 244–249.
  26. Molina JR, Aubry MC, Lewis JE, et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer. 2007; 110(10): 2253–2259.
  27. Afshar N, English DR, Blakely T, et al. Differences in cancer survival by sex: a population-based study using cancer registry data. Cancer Causes Control. 2018; 29(11): 1059–1069.
  28. Barquín M, Calvo V, García-García F, et al. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiol. 2020; 67: 101737.
  29. Hsu LH, Chu NM, Liu CC, et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer. 2009; 66(2): 262–267.
  30. Ferguson M, Wang J, Hoffman P, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2000; 69(1): 245–249.
  31. Minami H, Yoshimura M, Miyamoto Y, et al. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest. 2000; 118(6): 1603–1609.
  32. Radzikowska E, Głaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 2002; 13(7): 1087–1093.
  33. Radzikowska E, Głaz P. [The role of sex as a prognostic factor in lung cancer]. Pneumonol Alergol Pol. 2000; 68(9-10): 425–433.
  34. Ellington CL, Goodman M, Kono SA, et al. Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer. 2012; 118(18): 4444–4451.
  35. Yang H, Yao F, Tantai J, et al. Resected Tracheal Adenoid Cystic Carcinoma: Improvements in Outcome at a Single Institution. Ann Thorac Surg. 2016; 101(1): 294–300.
  36. Båtevik R, Grong K, Segadal L, et al. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer. 2005; 47(2): 173–181.
  37. Wolf M, Holle R, Hans K, et al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991; 63(6): 986–992.
  38. Asmis TR, Ding K, Seymour L, et al. National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008; 26(1): 54–59.
  39. Wang Y, Hunt K, Nazareth I, et al. Do men consult less than women? An analysis of routinely collected UK general practice data. BMJ Open. 2013; 3(8): e003320.
  40. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005; 49(6): 616–623.
  41. Hamidi M, Moody JS, Kozak KR. Refusal of radiation therapy and its associated impact on survival. Am J Clin Oncol. 2010; 33(6): 629–632.
  42. Mok T, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009; 361(10): 947–957.
  43. Radkiewicz C, Dickman PW, Johansson AL, et al. Sex and survival in non-small cell lung cancer: A nationwide cohort study. PLoS One. 2019; 14(6): e0219206.



Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory